Caroline Pothet: Advancing Treatment Development in Sickle Cell Disease and Thalassaemia
Caroline Pothet, Head of advanced therapies and haemato-oncology at the European Medicines Agency, shared a post on LinkedIn:
“Sickle cell disease and thalassaemia remain areas of significant unmet medical need. Advancing treatment options starts with supporting robust, innovative medicine development.
The release of two new EMA draft guidelines is an important step towards this goal, helping guide the development of new treatments for patients who need them. Thanks to Caroline Voltz Girolt and both drafting groups for driving this.
This is your turn to contribute by reviewing the guidelines and sharing your feedback:
Draft guideline on sickle cell disease
Draft guideline on thalassaemia
The public consultation is open until 31 January 2027.”
Stay updated with Hemostasis Today.
-
Nov 12, 2026, 14:35Mokhtar Tazik: Connecting Clinical Demand with Plasma Collection and Fractionation Capacity
-
Nov 12, 2026, 14:25Kim Phelan: Celebrating Dr. Marilyn Manco-Johnson as a Recipient of the 2026 Eternal Spirit Award
-
Nov 12, 2026, 14:20Shailesh Kucha: Ensuring Transfusion Safety Through Biochemical Assessment of Stored Red Cells
-
Nov 12, 2026, 14:20Akshat Jain: Wonderful Time Presenting at the ATHN 2026
-
Nov 12, 2026, 14:08Elisa Gabinaud: The Evolving Science of Megakaryocyte Development
-
Nov 12, 2026, 13:57Seyed Mohammad Sadegh Pezeshki: When Microcytosis Reveals a Complex Hemoglobinopathy
-
Nov 12, 2026, 13:45Danny Hsu: THANZ Highlights Antiphospholipid Syndrome in Upcoming Educational Webinar
-
Nov 12, 2026, 13:04Wuhan Thrombosis Congress 2026 – Bringing Global Experts Together – ISTH
-
Nov 12, 2026, 13:00Abdul Mannan: Factor IX Prophylaxis – Can Breakthrough Bleeding Still Occur?